Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27012810.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0370 and PMC identifier 4930675.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer. Dose escalation in patients with low endoxifen concentrations could enhance treatment efficacy. This approach is clinically feasible, and successfully increases endoxifen concentrations; however, it is unknown whether patients benefit from individualized tamoxifen dose escalation. Clin Cancer Res; 22(13); 3121-3. ©2016 AACRSee related article by Fox et al., p. 3164.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Tamoxifen